Structural MRI
Diagnostic TestWe will examine migraine and epilepsy patients as well as healthy controls using conventional structural MRI in the brain and spinal cord including T1-, T2-, and T2*-weighted sequences
NCT Number: NCT05524493
In this project, the aim is to recruit patients with drug resistant epilepsy and those suffering from migraine. Interestingly, patients suffering from epilepsy are also more often reporting to suffer from migraine. The pathobiology is understudied, but it is believed that both etiologies results from brain networks changes. A clinical certified 7T Terra Siemens scanner will be employed to assess in all participants (including healthy controls) how the microstructure differs in disease specific areas. Patients will further be clinically assessed as well as undergo questionnaires.
Migraine is also a common comorbidity to visual snow syndrom and has been shown to impact similar brain regions. However, the pathophysiology is still understudied and a better understanding of the two diseases is needed.
Interested in participating?
Request Info18 year–65 year
All sexes
Observational
Klinik Lengg, Zurich, Switzerland
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients:
Healthy participants;
Exclusion criteria
We will examine migraine and epilepsy patients as well as healthy controls using conventional structural MRI in the brain and spinal cord including T1-, T2-, and T2*-weighted sequences
We will examine migraine and epilepsy patients as well as healthy controls using quantitative MRI in the brain and spinal cord. This includes multi-parameter mapping (MPM) and quantitative susceptibility mapping (QSM).
We will examine migraine and epilepsy patients as well as healthy controls using diffusion MRI in both brain and spinal cord.
We will examine migraine and epilepsy patients as well as healthy controls using resting-state and task fMRI (including sensory stimulation using pain stimulus) in both brain and spinal cord.
We will examine migraine and epilepsy patients as well as healthy controls using MR Spectroscopy in both brain and spinal cord.
Time frame: Once during visit 2 (1-2 weeks after visit 1)
Time frame: Once during visit 2 (1-2 weeks after visit 1)
Time frame: Once during visit 2 (1-2 weeks after visit 1)
Time frame: Once during visit 2 (1-2 weeks after visit 1)
Time frame: Once during visit 2 (1-2 weeks after visit 1)
Time frame: Once during visit 2 (1-2 weeks after visit 1)
Time frame: Once during visit 2 (1-2 weeks after visit 1)
Time frame: Once during visit 2 (1-2 weeks after visit 1)
Time frame: Once during visit 2 (1-2 weeks after visit 1)
Time frame: Once during visit 1 (1-2 weeks prior to visit 2)
Time frame: Once during visit 1 (1-2 weeks prior to visit 2)
Modified questionnaire including personal and socio-demographic, diagnostic questions related to migraine, and enquiry into headache-related burden without strict scale
Time frame: Once during visit 1 (1-2 weeks prior to visit 2)
Time frame: Once during visit 1 (1-2 weeks prior to visit 2) for patients and once for healthy participants at MRI visit (1-2 weeks after inclusion into study)
0-42, higher score > higher probability of anxiety/ depression
Time frame: Once during visit 1 for patients (1-2 weeks prior to visit 2) and once for healthy participants at MRI visit (1-2 weeks after inclusion into study)
Time frame: Once during visit 1 (1-2 weeks prior to visit 2)
Time frame: Once during visit 1 (1-2 weeks prior to visit 2)
Time frame: Once during visit 1 (1-2 weeks prior to visit 2)
Time frame: Once during visit 1 (1-2 weeks prior to visit 2)
Time frame: Once during visit 1 (1-2 weeks prior to visit 2)
Time frame: Once during visit 1 (1-2 weeks prior to visit 2)
Which type of therapy (medication, behavioral therapy or neuromodulation)
Time frame: Once during visit 1 (1-2 weeks prior to visit 2)
Which type of therapy (medication, surgical intervention or neurostimulation)
Time frame: Once during visit 2 (1-2 weeks after visit 1)
The higher the score, the higher the impact of visual snow
Time frame: Once during visit 2 (1-2 weeks after visit 1)
Score from 0-100, the higher the score, the higher the vertigo impact
Contact information is provided by the study sponsor or research team.
University of Zurich
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06961864
Avitaminosis, Brain Diseases
Minneapolis, Minnesota, United States
View Trial DetailsNCT02670161
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Evanston, Illinois, United States
View Trial DetailsNCT06583395
Adnexal Diseases, Amyotrophic Lateral Sclerosis
Palm Desert, California, United States
View Trial DetailsNCT03847753
Acquired Immunodeficiency Syndrome, Allergy
View Trial Details